BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Nivolumab: trial readouts and FDA decisions

6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Bristol-Myers Squibb, BicycleTx Limited, Exelixis, TaiRx, Inc., IDEAYA Biosciences, Sanofi, Corcept Therapeutics, Arcus Biosciences, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-15 est.P3Exelixis EXELNCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNon-Clear Cell Renal Cell Carcinomaactive not recruiting317
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P2TaiRx, Inc.NCT05257590 CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaHepatocellular Carcinoma; Advanced Cancerrecruiting95
2027-01-15 est.P2/P3IDEAYA Biosciences IDYANCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaMetastatic Uveal Melanomaactive not recruiting420
2027-01-19 est.P1/P2Sanofi SNYNCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSolid Tumorrecruiting542
2027-02-05 est.P2Bristol-Myers Squibb BMYNCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously UnNon-Small Cell Lung Canceractive not recruiting76

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-30 est.P1/P2Bristol-Myers Squibb BMYNCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting100
2026-09 est.P1/P2Corcept Therapeutics CORTNCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesNeoplasmsrecruiting50
2026-08-28P3Arcus Biosciences, Inc. RCUSNCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That CAdvanced Upper Gastrointestinal Tract Adenocarcinomacompleted1040
2026-08 est.P1/P2BicycleTx LimitedNCT05163041 Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 ExpressionAdvanced Solid Tumoractive not recruiting200
2026-07-09P3Bristol-Myers Squibb BMYNCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaHepatocellular Carcinomacompleted732
2026-07 est.P3HUYABIO International, LLC.NCT04674683 Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaUnresectable or Metastatic Melanoma; Progressive Brain Metastasisactive not recruiting450
2026-05-27P3Bristol-Myers Squibb BMYNCT03383458 A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationHepatocellular Carcinoma; Liver Canceractive not recruiting545

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.